Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYML-122 in FLT3 Positive Relapsed or Refractory AML
NCT05241106Phase 2Recruiting
- Sponsor
- Tarapeutics Science Inc
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CHMFL-FLT3-122 in acute myeloid leukemia (AML), sponsored by Tarapeutics Science Inc. Started Sep 2021; status: recruiting.
02
Drugs
CHMFL-FLT3-122
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05241106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241106.